
Mirum Pharmaceuticals (($MIRM)) has held its Q3 earnings call. Read on for the main highlights of the call. Mirum Pharmaceuticals delivered a strongly positive earnings call, led by record product
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals | 91.95 | 19.76 | 27.37% |
| Name | Price | % Change | |
|---|---|---|---|
| $91.95 | +27.37% |

Mirum Pharmaceuticals (($MIRM)) has held its Q3 earnings call. Read on for the main highlights of the call. Mirum Pharmaceuticals delivered a strongly positive earnings call, led by record product

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Mirum Pharmaceuticals, with a price target of $202.00. Swayampakula Ramakanth’s rating is based on several

Citi raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $194 from $184 and keeps a Buy rating on the shares. The firm says the success of the AZURE-4

Mirum Pharmaceuticals (MIRM) announced that the primary endpoint was met in the Phase 3 AZURE-4 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on MIRM stock, giving a Buy rating yesterday. Jessica Fye’s rating is based on several factors, including brelovitug’s strong clinical

An update from Mirum Pharmaceuticals ( ($MIRM) ) is now available. On November 10, 2026, Mirum Pharmaceuticals announced that brelovitug met the primary endpoint in the Phase 3 AZURE-4 study

Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Mirum Pharmaceuticals and keeping the price target at $184.00. Yigal Nochomovitz’s rating is based on several factors, including his view

In a report released on November 3, Joseph Thome from TD Cowen maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $145.00. Joseph Thome’s rating is based

GeneDx (WGS) announced a collaboration with Mirum (MIRM) to offer no-cost exome testing for eligible patients across three sponsored testing programs: cholestasis, early-onset cataracts, and peroxisomal biogenesis disorder-Zellweger spectrum disorders.

Mirum Pharmaceuticals (MIRM) has disclosed a new risk, in the Litigation & Legal Liabilities category. Mirum Pharmaceuticals appears increasingly exposed to complex global data privacy and security regimes, given its
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Assigned | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Assigned | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 10, 2027TBA | $5.98B | $-0.63 | $195.60M | 2.25 | -6.10 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.